Ryan J. Watts sold $7.4M of DNLI
President and CEO at Denali Therapeutics Inc.. 495,282 shares at an average of $15.00, traded Jul 9, 2025, filed Jul 11, 2025.
Score components
- +25RoleCEO
- +25Trade size$7.4M at market
- +20Share of holdings soldSold 66% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001714899-25-000149, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 9, 2025 | MOption exercise Common Stock10b5-1 | +455,282 | $0.68 | $310k | 708,353 | Jul 11, 2025 |
| Jul 9, 2025 | MOption exercise Common Stock10b5-1 | +40,000 | $5.28 | $211k | 748,353 | Jul 11, 2025 |
| Jul 9, 2025 | SOpen-market sale Common Stock10b5-1 | -495,282 | $15.00 | $7.4M | 253,071 | Jul 11, 2025 |
| Jul 9, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -455,282 | $0.00 | $0 | 622,809 | Jul 11, 2025 |
| Jul 9, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 20,369 | Jul 11, 2025 |
Related signals
Other insiders at Denali Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Denali Therapeutics Inc. | Peter Scott Chin Chief Medical Officer | $37k 1,654 shares | -1% | |
| 33Weak | Denali Therapeutics Inc. | Nancy Thornberry director | $262k 11,439 shares | -37% | |
| 18Weak | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $65k 2,768 shares | -1% | |
| 10Weak | Denali Therapeutics Inc. | Carole Ho Chief Medical Officer | $52k 3,743 shares | -2% | |
| 29Weak | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $40k 2,937 shares | -1% | |
| 43Moderate | Denali Therapeutics Inc. | Steve E. Krognes director | $69k 3,339 shares | -11% | |
| 67Notable | Denali Therapeutics Inc. | Ryan J. Watts President and CEO | $751k 36,916 shares | -13% | |
| 44Moderate | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $308k 15,162 shares | -6% | |
| 44Moderate | Denali Therapeutics Inc. | Carole Ho Chief Medical Officer | $308k 15,162 shares | -8% | |
| 18Weak | Denali Therapeutics Inc. | Vicki L Sato director | $64k 3,080 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.